Int J Med Sci 2020; 17(17):2744-2750. doi:10.7150/ijms.50169

Research Paper

Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer

Meihong Chen1,2, Xiaoqing Lin1,3, Liangming Zhang1,3, Lili Yu1,3, Qingwei Wu1,3, Songgao Zhang1,3, Fangqin Xue1,4, Yi Huang1,3,5,6✉

1. Provincial Clinical College, Fujian Medical University, Fuzhou 350001, China.
2. Department of Clinical Laboratory, Fujian Provincial Hospital Jinshan Branch, Fuzhou 350001, China.
3. Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou 350001, China.
4. Department of Gastrointestinal Surgery, Fujian Provincial Hospital, Fuzhou 350001, China.
5. Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou 350001, China.
6. Key laboratory, Fujian Provincial Hospital, Fuzhou 350001, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Chen M, Lin X, Zhang L, Yu L, Wu Q, Zhang S, Xue F, Huang Y. Development of a panel of serum IgG and IgA autoantibodies for early diagnosis of colon cancer. Int J Med Sci 2020; 17(17):2744-2750. doi:10.7150/ijms.50169. Available from http://www.medsci.org/v17p2744.htm

File import instruction

Abstract

Purpose: Our pilot study in a small cohort by ELISA showed that the levels and positive rates of serum IgG autoantibodies against p53, HRAS and NSG1, and IgA autoantibody against TIF1γ in early colon cancer (CC) group were significantly higher than that of colon benign lesion (CBL) group / healthy control (HC) group (P <0.01), which suggested that four autoantibodies might be valuable for the diagnosis of patients with CC at early stage. On the basis of pilot study, we intend to comprehensively elucidate the performance of four autoantibodies for the early diagnosis of CC in a large sample cohort, and explore the optimal panel of autoantibodies in the diagnosis of patients with CC at early stage.

Methods: Western blot was used to define the ELISA results of serum anti-p53, HRAS, NSG1-IgG and anti-TIF1γ-IgA. The performances of anti-p53, HRAS, NSG1-IgG and anti-TIF1γ-IgA were evaluated by ELISA for the early diagnosis of CC with 601 serum samples of 157 patients with CC at early stage, 144 patients with CC at advanced stage, 130 patients with CBL, and 170 HC, and then the performances of different combinations of four autoantibodies were analyzed for the development of an optimal panel for the early diagnosis of CC.

Results: The results of anti-p53, HRAS, NSG1-IgG and anti-TIF1γ-IgA in western blotting were consistent with that in ELISA. The levels and positive rates of anti-p53, HRAS, NSG1-IgG and anti-TIF1γ-IgA in early CC group were significantly higher than that in CBL group/HC group (P <0.01), while had no significant difference from that in advanced CC group (P >0.05), of which anti-TIF1γ-IgA showed the highest area under the receiver operating characteristic curve (AUC) of 0.716 for the patients with CC at early stage, with 25.5% sensitivity and specificity at 96.7%. Additionally, a panel of anti-p53, HRAS-IgG and anti-TIF1γ-IgA showed the highest AUC among all possible combinations of four autoantibodies, up to 0.737, with 47.1% sensitivity at 92.0% specificity.

Conclusions: Serum IgG autoantibodies against p53, HRAS and NSG1, and IgA autoantibody against TIF1γ show the diagnostic value for the patients with CC at early stage, of which anti-TIF1γ-IgA is demonstrated to be a preferable biomarker, and an optimal panel comprised of anti-p53, HRAS-IgG and anti-TIF1γ-IgA might contribute to the further improvement of early diagnosis for CC.

Keywords: colon cancer, early diagnosis, autoantibody, combined detection